Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 10/20 | 0.47 |
| ▸ | ABL2 | P42684 | 6/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330471 | 0.91 | EGFR (0.51) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL20227770 | 0.91 | EGFR (0.51) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21330477 | 0.91 | ABL1 (0.51) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21330478 | 0.91 | ABL1 (0.51) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21351228 | 0.90 | ABL1 (0.42) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21298661 | 0.89 | KDR (0.43) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21351229 | 0.87 | EGFR (0.43) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21330454 | 0.85 | EGFR (0.43) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL21330453 | 0.85 | EGFR (0.43) | EGFRBRAFABL1ABL2MAPK14 | |
| SCHEMBL20214713 | 0.83 | ABL1 (0.59) | EGFRBRAFABL1ABL2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | EGFR 2930/4885BRAF 1396/4885ABL1 1855/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | EGFR 2930/4885BRAF 1396/4885ABL1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.